Abstract: A mining mobile communication system includes a first subsystem configured for communication in a licensed frequency band.

Abstract: A device for optimizing parameters of a deep neural network is included in an integrated circuit apparatus. The integrated circuit apparatus includes a general interconnection interface and other processing apparatus. A computing apparatus interacts with other processing apparatus to jointly complete a computing operation specified by a user. The integrated circuit apparatus further includes a storage apparatus. The storage apparatus is connected to the computing apparatus and other processing apparatus, respectively. The storage apparatus is used for data storage of the computing apparatus and other processing apparatus.

Abstract: Systems and methods are provided for performing random walk graph computing. One method may comprise generating a subset of walkers on a graph, maintaining the generated subset of walkers in a walker pool in a memory, loading a coarse-grained block of the graph from a non-volatile storage into a block buffer of the memory, generating pre-sampled edges for vertices in the coarse-grained block, storing the pre-sampled edges into a pre-sampled edge buffer allocated for the coarse-grained block and moving one or more walkers of the generated subset of walkers using the pre-sampled edges stored in the pre-sampled edge buffer. The generated subset of walkers may have an initial number determined based on a memory space allocated to the walker pool.

Abstract: The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (1).

Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Abstract: A perovskite light-emitting diode and a method of manufacturing the same are provided. The method includes steps of providing a substrate, disposing a first electrode layer, a hole transport layer, and a perovskite precursor liquid layer on the substrate, coating the perovskite precursor liquid layer with a first solvent, performing a first thermal process to form a perovskite prefabricated layer, coating the perovskite prefabricated layer with a second solvent, and performing a second thermal process to form a perovskite light-emitting layer.

Abstract: The present invention discloses a display device and a manufacturing method thereof having a light emission backplate, color conversion layer and a color film layer. The color conversion layer includes a red light conversion unit, a green light conversion unit, and an opening unit. The red light conversion unit and/or green light conversion unit includes calcium titanate light emitting material and scattering particles stacked in the calcium titanate light emitting material. In a vertical direction pointing from a surface of the color conversion layer near the light emission backplate to a surface away from the light emission backplate, a refractive index of the scattering particles gradually increases.

Abstract: Systems and methods are provided for performing random walk graph computing. One method may comprise generating a subset of walkers on a graph, maintaining the generated subset of walkers in a walker pool in a memory, loading a coarse-grained block of the graph from a non-volatile storage into a block buffer of the memory, generating pre-sampled edges for vertices in the coarse-grained block, storing the pre-sampled edges into a pre-sampled edge buffer allocated for the coarse-grained block and moving one or more walkers of the generated subset of walkers using the pre-sampled edges stored in the pre-sampled edge buffer. The generated subset of walkers may have an initial number determined based on a memory space allocated to the walker pool.

Abstract: Systems and methods are provided for performing temporal graph computing. One method may include ordering out edges in a candidate edge set of a vertex in deceasing time, grouping the out edges into a plurality of trunks with at least one of the plurality of trunks being a multi-edge trunk having two or more edges, generating a plurality of alias tables to record content of the plurality of trunks, performing inverse transform sampling on the plurality of trunks to choose a first trunk of interest, determining that the first trunk of interest is a complete multi-edge trunk with a plurality of edges arranged in a plurality of buckets and each bucket has an average weight of a total weight of the plurality of edges and sampling an edge from the plurality of edges by alias table sampling.

Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Abstract: The present invention discloses a display device and a manufacturing method thereof having a light emission backplate, color conversion layer and a color film layer. The color conversion layer includes a red light conversion unit, a green light conversion unit, and an opening unit. The red light conversion unit and/or green light conversion unit includes calcium titanate light emitting material and scattering particles stacked in the calcium titanate light emitting material. In a vertical direction pointing from a surface of the color conversion layer near the light emission backplate to a surface away from the light emission backplate, a refractive index of the scattering particles gradually increases.

Abstract: A display panel and a manufacturing method of the display panel are provided. The display panel includes: a first electrode, a second electrode disposed opposite to the first electrode, at least two light-emitting units and at least one charge generation layer disposed between the first electrode and the second electrode, wherein at least one of the light-emitting units is doped with quantum dot light-emitting material, and light emitted by each of the light-emitting units are blended to form white light.

Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Abstract: A perovskite film, method of preparing thereof, and an optoelectronic device are provided. They are prepared by steps including preparing a mixture containing a first monomer and a second monomer which can be crosslinked in situ; performing an annealing process, and the first monomer and the second monomer are reacted in situ to form a first polymer which combines with the perovskite crystal grains formed by the perovskite precursor and is concentrated at a crystal grain boundary of the perovskite crystal grains to passivate the perovskite crystal grain defects, and then a perovskite film is formed by curing.

Abstract: The present application provides a quantum dot ink and a display terminal. Components of the quantum dot ink include a low-molecular-weight silicon polymer which includes three organosilicon group directly connected to a nitrogen atom and each independently containing a silicon-oxygen bond as a skeleton and containing an amide or ester branched chain, such that the interaction of multiple hydrogen bonds in the low-molecular-weight silicon polymer is used to enhance the adhesion of the quantum dot ink after curing into a film, and meanwhile, the film is provided with self-repair properties.